R. Sinha

A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours

M. Janicot, W. Aherne, J. Bono, 2007 .

Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds.

K. El-Bayoumy, R. Sinha, Karam El-Bayoumy, 2004, Current cancer drug targets.

A review on myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.

Archana Singh, Sujata Singh, Pooja Mittal, 2021, International journal of biological macromolecules.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

M. Dowsett, D. Dearnaley, C. Parker, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

J. Bono, J. D. de Bono, S. Engelholm, 2010, British Journal of Cancer.

Cancer drug resistance

J. Bono, V. Karavasilis, A. Reid, 2008 .

Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial

Martin O. Leach, David J. Collins, Anwar R. Padhani, 2009, European Radiology.

A phase I/II study of the safety and anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors

P. B. Jensen, S. Engelholm, J. Bono, 2007 .

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

J. Bono, S. Engelholm, R. Penson, 2010, British Journal of Cancer.